Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Monopar Therapeutics Inc. - Common Stock
(NQ:
MNPR
)
69.92
-0.73 (-1.03%)
Delayed Quote
Updated: 12:58 PM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Monopar Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Crude Oil Down 2%; Maravai LifeSciences Shares Spike Higher
↗
February 23, 2024
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index jumping more than 100 points on Friday. The Dow traded up 0.36% to 39,209.32 while the NASDAQ rose 0.01% to 16,042.80....
Via
Benzinga
Topics
Stocks
Dow Surges Over 150 Points; AerCap Posts Upbeat Earnings
↗
February 23, 2024
U.S. stocks traded higher this morning, with the Dow Jones index jumping more than 150 points on Friday.
Via
Benzinga
Topics
Stocks
Dow Gains Over 400 Points; Keurig Dr Pepper Shares Fall After Q4 Results
↗
February 22, 2024
U.S. stocks traded higher toward the end of trading, with the Dow Jones index jumping more than 400 points on Thursday. The Dow traded up 1.13% to 39,048.47 while the NASDAQ rose 2.93% to 16,037.52....
Via
Benzinga
Topics
Stocks
What's Going On With Cancer-Focused Monopar Therapeutics Stock Today?
↗
February 22, 2024
Monopar Therapeutics soars 36% in premarket trading on robust volume. Exciting preclinical data reveals MNPR-101's potent anti-tumor efficacy in targeting uPAR-expressing cancers.
Via
Benzinga
Recap: Monopar Therapeutics Q3 Earnings
↗
November 09, 2023
Via
Benzinga
Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
February 22, 2024
Shares of Etsy, Inc.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
February 22, 2024
Via
Benzinga
Crude Oil Rises 1%; US Jobless Claims Fall To 201,000
↗
February 22, 2024
U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping around 300 points on Thursday. The Dow traded up 0.67% to 38,872.01 while the NASDAQ rose 2.36% to 15,949.22. The S&P...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
February 22, 2024
Via
Benzinga
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
February 22, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
February 21, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
February 20, 2024
Via
Benzinga
Crude Oil Moves Lower; Summit Therapeutics Shares Plummet
↗
February 20, 2024
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 200 points on Tuesday. The Dow traded down 0.18% to 38,557.86 while the NASDAQ fell 1.30% to 15,570.84. The...
Via
Benzinga
Topics
Stocks
Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
February 20, 2024
Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results.
Via
Benzinga
Why Is Cancer Drug Focused Monopar Therapeutics Stock Trading Higher On Tuesday?
↗
February 20, 2024
Monopar Therapeutics surges 90% premarket with 3.94 million volume after HREC clearance for Phase 1 dosimetry trial (MNPR-101-Zr) in advanced cancers.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
February 20, 2024
Via
Benzinga
Dow Dips Over 100 Points; US Leading Economic Index Falls In January
↗
February 20, 2024
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 1.5% on Tuesday. The Dow traded down 0.35% to 38,494.51 while the NASDAQ fell 1.51% to 15,537.95. The S&P 500...
Via
Benzinga
Topics
Stocks
Nasdaq Down 1%; Capital One Set To Buy Discover
↗
February 20, 2024
U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 150 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.05% to 38,607.53 while the NASDAQ fell...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
February 20, 2024
Via
Benzinga
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
February 20, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
January 12, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
January 11, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
December 29, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
December 06, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
November 16, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
November 13, 2023
Via
Benzinga
Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
November 13, 2023
Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results.
Via
Benzinga
Why StoneCo Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
↗
November 13, 2023
StoneCo Ltd. (NASDAQ: STNE) shares rose in pre-market trading after the company reported upbeat results for its third quarter on Friday.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
November 13, 2023
Via
Benzinga
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
November 09, 2023
MNPR-101 Radiopharma Program to Enter First-in-Human Studies Potentially As Early As December of This Year Camsirubicin Phase 1b Trial Efficacy and Safety Data Highlighted at the 2023 CTOS Annual...
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
